RIKER LAUREN 4

What Happened Lauren Riker, Senior Vice President, Finance at Pacira BioSciences (PCRX), disposed of a total of 6,751 shares in two transactions totaling about $139,746. On 2026-01-30, 2,751 shares were withheld by the issuer to cover tax withholding on vested restricted stock units at $20.54 per share ($56,506). On 2026-02-02, 4,000 shares were sold in the open market under a pre-established Rule 10b5-1 plan at a weighted average price of $20.81 per share ($83,240; sales ranged $20.35–$21.28).

Key Details

• Transaction dates: 2026-01-30 (tax-withholding on RSUs) and 2026-02-02 (open-market sale).
• Prices & values: 2,751 shares @ $20.54 = $56,506; 4,000 shares @ $20.81 (weighted avg; $20.35–$21.28) = $83,240; total ≈ $139,746.
• Footnotes: F1 = shares withheld by issuer for tax withholding on RSU vesting; F2 = open-market sale executed under a Rule 10b5-1 trading plan; F3 = weighted-average price with sales across the stated price range.
• Shares owned after the transactions are not disclosed in the provided filing.
• Filing: Form 4 filed 2026-02-03; timing appears consistent with standard Form 4 deadlines for these transactions.

Context Both actions are dispositions (not purchases). The 2,751-share transaction was a routine tax-withholding related to RSU vesting (common and not necessarily a directional signal). The 4,000-share sale was executed under a previously adopted 10b5-1 plan, indicating the sale was prearranged. For retail investors, purchases generally signal more about insider conviction than routine sales; these transactions appear to be administrative and preplanned.